Health company Essity stated on Wednesday that it has scaled up the production of its Tork-branded hand sanitizers capacity to meet the increased demand in Europe following the challenges, impact and focus of the COVID-19 pandemic on hand hygiene.
In the Q4 2020, the company will increase its supply capacity of hand sanitizer in Europe to enable the continued high growth of the existing range. Its Professional Hygiene business, under the leading global brand Tork, has seen a steep increase in demand for hand sanitizers in response to new hygiene regulations or customers' desire to provide an additional layer of safety where water and soap are not available.
Based on the research conducted on the company's behalf in July 2020, the hand hygiene is now an integral part of everyday routines and that 74% of people now consider hand hygiene to be more a part of their overall health routine than before the COVID-19 pandemic. About 69% of respondents find hand sanitizers a good complement to washing hands.
With an increase in the sanitizer capacity, the businesses and their employees and customers can offer consistent and reliable access to hand-hygiene products when handwashing is not readily available, concluded the company.
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Merck to acquire Terns Pharmaceuticals for USD6.7bn
Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD
Bio-Techne expands COMET spatial biology platform with new SPYRE Panels and Amplification Kits
CRISM Therapeutics advances Phase 2 glioblastoma trial with initial ChemoSeed batch manufactured
Myosin Therapeutics granted USD2m funding from Florida Department of Health
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Akeso's Phase II trials of AK146D1 and AK138D1 approved in China
Insilico Medicine and ASKA Pharmaceutical expand partnership on women's health targets
Pharming secures Japan approval for Joenja in rare immune disorder treatment
BioArctic and Eisai present new lecanemab and exidavnemab data at AD/PD 2026
HUTCHMED launches Phase III trial of HMPL-760 for DLBCL in China
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate